Metabolic syndrome
The cluster of findings — central adiposity, dysglycaemia, dyslipidaemia, raised blood pressure — that tend to travel together.
Metabolic syndrome describes a cluster of findings that co-occur more often than chance: central adiposity, impaired glucose regulation, atherogenic dyslipidaemia, and raised blood pressure. It is a description of a pattern rather than a single disease, and the definition has been revised repeatedly — a fair criticism of the concept.
Its usefulness is in emphasising that these findings share mechanisms rather than merely coinciding. Insulin resistance and adipose tissue dysfunction link them, which is why interventions acting on energy balance tend to move several components at once rather than one.
That is the context in which incretin-based research extended past glucose. If the components are mechanistically connected, an intervention that shifts the underlying state might plausibly affect cardiovascular and renal outcomes too — a hypothesis that required large outcome trials, not inference, to test.
Related articles
- MetabolicGLP-1 receptor agonistsHow GLP-1 works, and why molecules mimicking it became central to metabolic research.
- MetabolicCardiovascular and renal findings in incretin researchWhy outcome trials — not surrogate markers — reshaped how incretin science is understood.
- MetabolicThe incretin effectThe observation that started incretin science: glucose taken by mouth triggers far more insulin than the same glucose given intravenously.
- MethodsBiomarkers and surrogate endpointsMeasuring something easy in place of something that matters — useful, and quietly dangerous.
- MetabolicGIP and its receptorThe other incretin hormone — long overshadowed by GLP-1, now central to combination approaches.
- MetabolicDual GIP/GLP-1 receptor agonistsEngineering one molecule to engage two incretin receptors — and what head-to-head data showed.